AngioDynamics,
Inc. Lippert/Heilshorn
& Associates, Inc.
Lisa
Donegan Kim Sutton Golodetz
(kgolodetz@lhai.com)
(800)
772-6446 x370 (212) 838-3777
www.angiodynamics.com Bruce
Voss (bvoss@lhai.com)
(310)
691-7100
FOR IMMEDIATE RELEASE
ANGIODYNAMICS ANNOUNCES AVAILABILITY OF ANGIOFLOWä THERMAL
DILUTION CATHETER AND ANGIOFLOWä METER IN THE U.S.
Queensbury, NY; April 20, 2004 -- AngioDynamics, Inc., a wholly
owned subsidiary of
E-Z-EM, Inc., (AMEX: EZM) today announced the introduction
of the AngioFlowä Thermal Dilution Catheter and
AngioFlow Meter in the United
States, collectively
known as the AngioFlow System. The AngioFlow System is a catheter-based flow
meter the Company believes will be the first device to measure blood flow in
hemodialysis access sites during an access site clearing procedure.
Maintaining the patency of a vascular access graft or
fistula is critical to the survival of patients with chronic renal failure.
Several studies have determined that a blood flow less than 600ml/min is
predictive of a developing stenosis within a graft or fistula. If left
untreated, the graft or fistula will occlude, and the patient will be unable to
undergo hemodialysis treatment. Multiple endovascular and surgical
interventions are frequently required to maintain patency of a vascular
access. The AngioFlow System provides accurate and immediate blood flow
measurements during these interventions.
Dr. Tom Vesely, an Associate Professor of Radiology,
Surgery, and Medicine at the Washington University School of Medicine in Saint Louis, has extensive clinical experience
with the AngioFlow system. Commenting on this technology, Dr. Vesely stated,
“The AngioFlow system provides valuable and immediate information that is
useful for the detection of inconspicuous lesions, optimizing our reparative
procedures, and helping to restore full function to the patient’s vascular
access.”
Commenting for AngioDynamics, Don Geer, Director of
Marketing for Vascular Access Products, said, “Due to the aging of the
population and other factors, the long-term care of patients with chronic renal
failure is a growing medical problem. The AngioFlow System helps physicians
treat these patients by providing important data on blood flow through the
vascular access graft site, and as such represents an important addition to
AngioDynamics’ dialysis product line. We are pleased to able to bring this
important product to physicians and their patients.”
For additional information on the AngioFlow catheter and
AngioFlow meter, contact Don Geer at 1-800-772-6446, ext. 167, Email:
dgeer@angiodynamics.com or visit the AngioDynamics web site at www.angiodynamics.com.
About AngioDynamics
AngioDynamics, Inc. (www.angiodynamics.com) manufactures a wide range of products,
including angiographic, dialysis, PTA dilation, thrombolytic, image-guided
vascular access, endovascular laser venous system, as well as abdominal
infection drainage products. AngioDynamics' focus is on diagnostic and
therapeutic products that enable interventional physicians to treat peripheral
vascular diseases and other non-coronary diseases.
About EZEM
E-Z-EM is a leading manufacturer of contrast agents for
gastrointestinal radiology. The Company has developed the only CT injector on
the market that can help detect contrast extravasation, the EmpowerCT® with patented EDA™ technology; it also
offers a complete product set for the virtual colonoscopy practitioner. This
product line consists of virtual colonoscopy hardware, software, nutritional
prep kits and bowel cleaners, tagging agents and a carbon dioxide colon
insufflation system.
The statements made in this document contain certain forward‑looking
statements that involve a number of risks and uncertainties. Words such as
“expects”, “intends”, “anticipates”, “plans”, “believes”, “seeks”, “estimates,”
or variations of such words and similar expressions, are intended to identify
such forward-looking statements. Investors are cautioned that actual events or
results may differ from the Company’s expectations. In addition to the matters
described above, the ability of the Company to develop its products, market
acceptance of AngioFlow Thermal Dilution Catheter and AngioFlow Meter, future
actions by the FDA or other regulatory agencies, results of pending or future
clinical trials, overall economic conditions, general market conditions,
foreign currency exchange rate fluctuations, the effects on pricing from group
purchasing organizations, competition, as well as the risk factors listed from time
to time in the SEC filings of E-Z-EM, Inc., including but not limited to its
Form 10-Q for the quarter ended February 28,2004, as well as its Annual Report
on Form 10-K for the year ended May 31, 2003, may affect the actual results
achieved by the Company.
# # #
